Drug Trial Radar · NCT06684314
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
79
Actual
Start
Nov 11, 2024
Primary completion
Aug 28, 2031
Study completion Aug 28, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a national, multicenter, retrospective/prospective, observational study in Taiwan designed to assess effectiveness, safety, and usage of efanesoctocog alfa prophylaxis treatment in hemophilia A participants. The data related to efanesoctocog alfa effectiveness, safety and usage will be recorded prospectively during routine visits for up to 5 years following enrollment initiation and the retrospective data will be collected at least 12 months and up to 24 months prior to efanesoctocog alfa initiation. Joint imaging data will be collected in centers performing Joint U/S and/or MRI (≥6 years old). At least 12 months of retrospective data will also be collected from medical records, as available. Prospectively collected data will be recorded at routine clinical visits during a five-year follow-up period. The end of study is defined as the last participant's last visit. No intervention will be administered, and no study related visits are required.
Conditions
- Hemophilia A
Interventions
Efanesoctocog alfaDrug
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all jointsTime frame: At 1, 2, 3, 4 and 5 years
- Change from baseline in annualized joint bleeding rate (AjBR) for treated and untreated bleedsTime frame: At 1, 2, 3, 4 and 5 years
- Number of target joint development, resolution and/or recurrenceTime frame: At 1, 2 ,3, 4 and 5 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 1580008
Changhua, Taiwan
Investigational Site Number : 1580009
Kaohsiung City, Taiwan
Investigational Site Number : 1580010
Kaohsiung City, Taiwan
Investigational Site Number : 1580003
New Taipei City, Taiwan
Investigational Site Number : 1580005
Taichung, Taiwan
Investigational Site Number : 1580006
Taichung, Taiwan
Investigational Site Number : 1580007
Taichung, Taiwan
Investigational Site Number : 1580001
Taipei, Taiwan
Investigational Site Number : 1580002
Taipei, Taiwan
Investigational Site Number : 1580004
Taoyuan City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.